Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 143 clinical trials
Rituximab in Patients With ST-elevation Myocardial Infarction (RITA-MI2)

acute anterior STEMI. The primary endpoint is the left ventricular ejection fraction (LVEF) by CMR at 6 months.

  • 0 views
  • 17 Jun, 2022
STaged Interventional Strategies for Acute ST-seGment Elevation Myocardial Infarction Patient With Multi-vessel Disease STAGED

An investigator-initiated, randomized, multicenter, two-arm, open-label study of consecutive patients presenting with STEMI and MVD Objectives: The present study aimed to investigate the

  • 0 views
  • 14 Jun, 2021
  • 1 location
Clinical Efficacy and sAfety of Intravenous Infusion of Nicorandil During Primary Percutaneous Coronary Intervention

(STEMI) patients undergoing primary percutaneous coronary intervention (PCI).

reperfusion therapy
stemi
percutaneous coronary intervention
  • 0 views
  • 05 Aug, 2021
  • 1 location
iFR Guided Multi-vessel Revascularization During Percutaneous Coronary Intervention for Acute Myocardial Infarction

In patients with acute ST-elevation myocardial infarction (STEMI), 40-60% have multi-vessel disease with an increased cardiovascular morbidity and mortality. Although it is not recommended to

percutaneous coronary intervention
stemi
stenosis
  • 0 views
  • 16 Dec, 2021
  • 1 location
Direct Complete Versus Staged Complete Revascularization in Patients Presenting With Acute Coronary Syndromes and Multivessel Disease (BioVasc)

Non-ST-elevation ACS (NSTEACS) and ST-elevation myocardial infarction (STEMI), with multivessel disease accepted for PCI

angiography
ischemia
troponin
acute coronary syndrome
stemi
  • 0 views
  • 12 Feb, 2022
  • 1 location
Colchicine and Spironolactone in Patients With MI / SYNERGY Stent Registry (CLEAR SYNERGY)

The CLEAR SYNERGY trial will study the long term effects of treatments following PCI to treat myocardial infarction. These treatments address both the culprit artery (PCI with SYNERGY stent) as well as the non-culprit arteries (randomization to routine colchicine and spironolactone).

troponin
stemi
diabetes
colchicine
  • 23 views
  • 01 Mar, 2022
  • 1 location
Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI

AMUNDSEN-real is a phase IV, international (7 European countries), multicenter, controlled, open label study randomized, in 2 parallel groups of patients with a diagnosis of STEMI or NSTEMI with

  • 0 views
  • 10 Oct, 2021
Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome (ELECTRA-SIRIO)

The ELECTRA-SIRIO 2 study is a randomized, multicenter, double-blind, investigator-initiated clinical trial aimed to evaluate safety and efficacy of two ticagrelor-based de-escalation antiplatelet strategies in patients with acute coronary syndrome (ACS). During the hospitalization due to ACS, participants will be randomized in a 1:1:1 ratio into one of three arms: …

aspirin
acute coronary syndrome
antiplatelet therapy
ticagrelor
  • 0 views
  • 13 Mar, 2022
  • 1 location
Firehawk Rapamycin Target Eluting Coronary Stent North American Trial

treatment of subjects with ischemic heart disease (NSTEMI, recent STEMI (>24 hours from initial presentation and in whom enzyme levels have peaked), unstable angina, and stable coronary disease), with

biodegradable polymer
ischemia
troponin
coronary disease
everolimus
  • 0 views
  • 11 Jul, 2021
  • 25 locations
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)

[MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non

arterial disease
diabetes
stemi
infarct
myocardial infarction
  • 1233 views
  • 03 Jul, 2022
  • 1620 locations